Chiesi Group Partners with Salesforce to Enhance Customer Engagement
Chiesi Group, a global biopharmaceutical organization, has announced its collaboration with Salesforce to implement the Agentforce Life Sciences platform. This strategic move aims to transform Chiesi’s commercial operations and improve engagement with healthcare professionals worldwide. The partnership, revealed on April 20, 2026, is designed to create a more connected and responsive operational framework within the company.
Transforming Commercial Operations
The adoption of Agentforce Life Sciences represents a significant shift in how Chiesi supports both patients and healthcare professionals. By consolidating its operations onto a unified platform, Chiesi is set to enhance collaboration among its teams and streamline their processes. This transition will facilitate quicker responses to market needs and foster meaningful customer interactions.
Key objectives of this implementation include:
- Unified Data Foundation with Data 360: Chiesi plans to create a comprehensive view of healthcare professionals, hospitals, and pharmacies by consolidating customer data. Data 360 will serve as the backbone for integrating field interactions, medical affairs activities, and business operations, ensuring access to consistent and compliant information across various markets.
- Agentforce Powered Field Teams: Field representatives will benefit from AI-assisted tools that streamline tasks such as note-taking and planning for customer visits. This technology will allow them to dedicate more time to engaging in meaningful conversations with healthcare providers.
- Commercial Operations at Scale: With Agentforce Life Sciences for Customer Engagement, Chiesi’s teams will manage the complete lifecycle of healthcare professional engagement—from event coordination to multichannel marketing campaigns—enhancing overall operational efficiency.
Navigating Industry Challenges
The pharmaceutical sector faces numerous challenges, including geopolitical tensions, regulatory complexities, and evolving supply chain dynamics. These factors necessitate an agile approach to business operations. Recognizing these pressures, Chiesi’s leadership is committed to transforming its core business while adopting a science-led approach to innovation.
The company aims to introduce artificial intelligence (AI) gradually as a supportive tool that enhances decision-making processes and improves engagement with healthcare professionals. This strategy is expected to yield greater value for patients while maintaining compliance with industry regulations.
Fabio Mira, Senior VP and Chief Transformation Officer at Chiesi Group, emphasized the importance of this transformation: “At Chiesi, this transformation is about strengthening how we serve patients and healthcare professionals while enabling our teams to work in more connected and effective ways.”
A New Era for Life Sciences in Italy
The partnership between Chiesi Group and Salesforce represents a pivotal moment for the life sciences industry in Italy and beyond. Joe Ferraro, SVP and GM of Agentforce Life Sciences, highlighted the significance of this collaboration: “Chiesi’s selection of Salesforce signals a transformative shift for the life sciences industry globally.” He noted that this partnership illustrates how pharmaceutical companies are moving away from outdated customer relationship management (CRM) systems towards AI-driven platforms that facilitate substantial commercial transformation.
Vanessa Fortarezza, Country Manager for Salesforce Italy, echoed these sentiments by stating that Chiesi exemplifies modern Italian innovation—competitive on a global scale while being research-driven and purpose-led. She emphasized that this partnership would enable Chiesi to build resilient ecosystems driven by data.
Mira further elaborated on the human aspect of this transformation: “This is first and foremost a people-led transformation. Together with Salesforce, we are building a true partnership focused on empowering our employees with the tools they need to forge meaningful connections with healthcare professionals.”
What This Means for the Future
The collaboration between Chiesi Group and Salesforce signifies an important shift in how biopharmaceutical companies can leverage technology for improved operational efficiency and patient outcomes. By adopting advanced platforms like Agentforce Life Sciences, organizations can enhance their ability to respond swiftly to market demands while fostering better relationships with healthcare providers.
This initiative not only positions Chiesi at the forefront of digital transformation within the pharmaceutical sector but also sets a precedent for other companies looking to modernize their operations in an increasingly complex regulatory environment. The emphasis on responsible AI usage further underscores the commitment towards ethical practices in patient care and data management.
For more information, read the original report here.
